Early Onset Alzheimer disease (EOAD)

Early Onset Alzheimer disease (EOAD)

Approximately 5 to 10% of all Alzheimer disease patients are diagnosed before age 65. This “early onset” dementia (EOAD) is especially devastating, as patients begin experiencing symptoms often while still providing for their families, and often while still caring for parents or children. As such, it represents a substantial burden for patients, spouses, and their families.

While some forms of EOAD are well-studied (i.e., autosomal dominant, monogenic forms) most EOAD patients do not carry these well-described genetic risk factors. As such, there is a lack of understanding of EOAD. In particular, we do not fully understand what causes it, what influences its progression, how to predict it, nor how to treat it. As such, we at the John P. Hussman Institute for Human Genomics (HIHG) are conducting genomics research to study EOAD. These studies include both individuals with EOAD, as well as their families. Additionally, we are including individuals from all race and ethnic groups willing to participate.

University of Miami Principal Investigator

Gary Beecham, Ph.D.

Principal Investigator

Christiane Reitz, MD, Ph.D.- Columbia University

University of Miami Significant Collaborators

Margaret Pericak-Vance, Ph.D.
Michael Cuccaro, Ph.D.

If you or your family members would like more information on how you can participate in this study, please contact:

Francelethia Johnson, MAS
Clinical Research Coordinator
University of Miami Miller School of Medicine
John P. Hussman Institute for Human Genomics
Ph: (305) 243-1005
Email: hihgeoad@miami.edu